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Statement of translational relevance 78
We describe here the cellular basis and molecular mechanism underlying dasatinib-induced 79 pleural effusions and bleeding diathesis, which are some of the most common adverse effects of 80 this short-acting dual ABL/SRC tyrosine kinase inhibitor (TKI) Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 cadherin junctions compromise the barrier function. Importantly, junctions are also connected to 129 cell-matrix adhesions through the actin cytoskeleton. ECs make discrete contacts ("focal 130 adhesions") with the basement membrane. (13 DOI: 10.1158 /1078 Germany) and a 63x, 1.40NA PLANAPO oil objective. Images were acquired using LAS AF 187 software (Leica) 
231
Confluent HUVECs were treated with dasatinib 5nM, 10nM, 25nM, 50nM and 100nM for 3h.
232
The entire supernatant was collected and 7AAD was added. Events were acquired for 60sec with 5 nM and 10 nM dasatinib, we observed a mild decrease in impedance (Fig.1A) . In 266 contrast, 25 nM and 50 nM dasatinib induced a steep decrease, whereas 100 nM (a dose similar 267 to the levels found in the plasma of patients 1 h after oral uptake of 100 mg dasatinib) caused a 268 profound decrease in impedance (Fig.1A) . Conversely, treatment with 2 µM imatinib for 2 h 269 had no significant effect, and 10 µM decreased the impedance only slightly (Fig.1B) . Clinically 270 relevant concentrations of nilotinib (1 and 5 µM), bosutinib (100 and 500 nM) and ponatinib (20 271 and 100 nM) had no effect either on the impedance readings (Fig.1C) . The inhibitors were 272 dissolved in DMSO and diluted at least 1:5000 in cell culture media to avoid any effects to the 273 impedance (Fig.1D ).
274
To address whether the effect of dasatinib was due to non-reversible damage to the 275 endothelial monolayer, we removed the inhibitor, added fresh medium and measured the 276 impedance for another hour in the absence of dasatinib. Importantly, impedance quickly 277 recovered to levels comparable to those measured at the beginning of the experiment (Fig.1A) . Fig.2A) . We found that 10-25 nM dasatinib induced very small gaps between cells ( Fig.2A) 
285
and a modest decrease of the junctional F-actin (the F-actin found at the cell-cell contacts), DOI: 10.1158 /1078 entities or in small islets with a high percentage of protrusive cells as revealed by thin rims of F-291 actin at round edges ( Fig.2A, arrowheads) . Conversely, 10 µM of imatinib had no effects on the 292 monolayer.
294
Since the major effect of dasatinib focused on the cell-cell junctions, we examined these in more 295 detail by visualizing the adherens junction marker VE-cadherin, which was no longer detected 296 on the surface of dasatinib-treated HUVECs (Fig.2B) . However, dasatinib washout rapidly 297 restored VE-cadherin at the reformed cell-cell junctions. These data indicate that dasatinib 298 induces the rapid disappearance of VE-cadherin from the cell-cell contacts concomitant to their 299 dissolution.
300
We next analyzed the dynamics of contact dissolution and reformation using time-lapse 301 live-cell microscopy. By imaging confluent HUVECs every minute after the addition of 302 dasatinib, we observed that the drug quickly disrupted the cell-cell contacts, and large gaps 303 between the cells could be observed as early as 6 min after dasatinib addition (Fig.3A, upper 304 panels). After 1 h, the endothelial monolayer was disorganized and only scattered cell-cell 305 contacts remained. Individual, spindly, isolated cells were readily observed (Fig.3A, 
306
Supplemental video S1). Conversely, imatinib had no significant effect on the integrity of the 307 monolayers (Fig.3A, lower panels) . Again, dasatinib washout led to the rapid recovery of the 308 integrity of the monolayer, which was apparent after 10 min and comparable to untreated Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 cells, e.g. lamellipodia in cells in the rear cohorts ( Fig.2A, arrowheads) . These data suggest that 328 dasatinib does not prevent cell migration, but it inhibits the formation of intercellular contacts, Fig.5A-C) . These changes also altered the distribution of cell-matrix adhesions, which were 344 sharper and better defined in dasatinib-treated cells compared to control conditions (Fig.5D ).
345
Together, these data indicate that dasatinib increases the mesenchymal traits of endothelial cells,
346
perturbing the cell-cell junctions by increasing NMII-mediated contractility.
347
Next, we aimed at elucidating the specific mechanism by which dasatinib promotes 348 these changes in endothelial monolayers. Based on the alterations in NMII phosphorylation, we 349 hypothesized that ROCK was involved in the mechanism altered by dasatinib. To address this, 
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Dasatinib significantly increased the amount of Evans Blue in the small intestine 386 compared to the control group and the other TKIs (dasatinib mean 13.6, vehicle 1.0, imatinib 387 2.8, bosutinib 1.5 mg Evans Blue/mg tissue; p=0.0089) (Fig.6A, supplementary Fig.S5 ). The 388 amount of detected Evans Blue in the spleen was also higher in the mice which had been treated 389 with dasatinib (dasatinib mean 11.1, vehicle 6.6, imatinib 3.9, bosutinib 7.6 mg Evans Blue/mg 390 tissue; p=0.04) (Fig.6B) . In contrast, no significant differences of Evans Blue were found in the Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 Discussion 394
Many studies have reported the immune-related adverse effects of dasatinib. (7, (27) (28) (29) (30) (31) (32) (33) 395 However, these side-effects do probably not account for all the observed deleterious effects of 396 the treatment in human patients, e.g. pleural effusions and bleeding diathesis. These are critical 397 events that physicians take into account when prescribing the drug, but data on their molecular 398 basis remains scarce. Interestingly, we found that dasatinib, in contrast to the other studied 
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